BRISK-FL study with investigational compound brivanib in hepatocellular carcinoma does not meet overall survival primary endpoint [press release]. Princeton, NJ: Bristol-Myers Squibb; July 19, 2012. Available at: http://www.reuters.com/article/2012/07/19/idUS218420+19-Jul-2012+BW20120719 . Accessed July 20, 2012
Download Bibliographical Data
We do not assume any responsibility for the contents of the web pages of other providers.